Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Eli Lilly and Company
Kedrion S.p.A.
Medical College of Wisconsin
Pfizer
Pfizer
Assiut University
Dana-Farber Cancer Institute
Kelonia Therapeutics, Inc.
Fred Hutchinson Cancer Center